Neurological Surgery

Publications

Found 9 results
Author Title Type [ Year(Asc)]
Filters: Keyword is Genetic Therapy  [Clear All Filters]
2019
Kaplitt MG.  2019.  Gene-targeting approaches for movement disorders: recent advances.. Curr Opin Neurol. 32(4):566-570.
2018
Rosenberg JB, Kaplitt MG, De BP, Chen A, Flagiello T, Salami C, Pey E, Zhao L, Arbona RJRicart, Monette S et al..  2018.  AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease.. Hum Gene Ther Clin Dev. 29(1):24-47.
Niethammer M, Tang CC, Vo A, Nguyen N, Spetsieris P, Dhawan V, Ma Y, Small M, Feigin A, During MJ et al..  2018.  Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity.. Sci Transl Med. 10(469)
Stavarache MA, Petersen N, Jurgens EM, Milstein ER, Rosenfeld ZB, Ballon DJ, Kaplitt MG.  2018.  Safe and stable noninvasive focal gene delivery to the mammalian brain following focused ultrasound. J Neurosurg. 130(3):989-998.
2017
Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A et al..  2017.  Long-term follow-up of a randomized AAV2- gene therapy trial for Parkinson's disease.. JCI Insight. 2(7):e90133.
2016
Marongiu R, Arango-Lievano M, Francardo V, Morgenstern P, Zhang X, M Cenci A, Svenningsson P, Greengard P, Kaplitt MG.  2016.  Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice.. Proc Natl Acad Sci U S A. 113(5):1423-8.
2013
Gelfand Y, Kaplitt MG.  2013.  Gene therapy for psychiatric disorders.. World Neurosurg. 80(3-4):S32.e11-8.
2010
Alexander B, Warner-Schmidt J, Eriksson T, Tamminga C, Arango-Lievano M, Ghose S, Vernov M, Stavarache M, Musatov S, Flajolet M et al..  2010.  Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med. 2(54):54ra76.
2007
Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D et al..  2007.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 369(9579):2097-105.